Overview

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT neoadjuvant regimen in patients with stage III breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Spanish Breast Cancer Research Group
Collaborators:
Bristol-Myers Squibb
Eli Lilly and Company
Treatments:
Albumin-Bound Paclitaxel
Doxorubicin
Gemcitabine
Liposomal doxorubicin
Paclitaxel